246 related articles for article (PubMed ID: 18418043)
1. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Huang CH; Mandelker D; Gabelli SB; Amzel LM
Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
[TBL] [Abstract][Full Text] [Related]
2. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
4. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Zhao L; Vogt PK
Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
[TBL] [Abstract][Full Text] [Related]
5. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
[TBL] [Abstract][Full Text] [Related]
6. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Jaiswal BS; Janakiraman V; Kljavin NM; Chaudhuri S; Stern HM; Wang W; Kan Z; Dbouk HA; Peters BA; Waring P; Dela Vega T; Kenski DM; Bowman KK; Lorenzo M; Li H; Wu J; Modrusan Z; Stinson J; Eby M; Yue P; Kaminker JS; de Sauvage FJ; Backer JM; Seshagiri S
Cancer Cell; 2009 Dec; 16(6):463-74. PubMed ID: 19962665
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
[TBL] [Abstract][Full Text] [Related]
9. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
Dbouk HA; Pang H; Fiser A; Backer JM
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
[TBL] [Abstract][Full Text] [Related]
10. Human tumor mutants in the p110alpha subunit of PI3K.
Liu Z; Roberts TM
Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
[TBL] [Abstract][Full Text] [Related]
11. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
[TBL] [Abstract][Full Text] [Related]
13. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
14. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic mutations of PIK3CA in human cancers.
Samuels Y; Velculescu VE
Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468
[TBL] [Abstract][Full Text] [Related]
19. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus.
Jenkins ML; Ranga-Prasad H; Parson MAH; Harris NJ; Rathinaswamy MK; Burke JE
Nat Commun; 2023 Jan; 14(1):181. PubMed ID: 36635288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]